Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Fidelity Brokerage Services LLC filed a Form 144 reporting 2,085 shares of common stock for sale on 02/20/2026 tied to a restricted stock vesting event, listed on NASDAQ. The filing also records recent sales by Adam Laponis of 2,738, 3,000, and 7,000 common shares on 01/09/2026, 01/13/2026, and 02/12/2026 respectively, with dollar amounts shown for each sale.
Form 144 filing reports a proposed sale of 1,465 shares of common stock. The filing lists the sale date as 02/20/2026 and states the securities relate to restricted stock vesting described as compensation. The brokerage listed is Fidelity Brokerage Services LLC on NASDAQ.
The filing also discloses prior open-market sales by Paula Green: 12/08/2025 (877 shares for $28,833.66), 12/22/2025 (273 shares for $9,433.79), and 02/03/2026 (1,194 shares for $55,611.15).
Notice of proposed sale and recent transactions by Patrick Finn. The filing lists a restricted stock vesting event of 02/20/2026 covering 4,294 common shares tied to compensation. It also reports multiple sales by Patrick Finn in Jan–Feb 2026, including 68,967 shares sold on 02/17/2026 for $3,562,415.47.
Twist Bioscience reported insider sales by Robert F. Werner. The filing lists sales of Common Stock on 11/24/2025 (822 shares for $23,599.21), 12/08/2025 (230 shares for $7,561.85), 02/03/2026 (175 shares for $8,150.71), and 02/04/2026 (7,000 shares for $319,532.51).
The filing also lists Restricted Stock Vesting of 1,693 Common shares on 02/23/2026 tied to compensation.
Twist Bioscience Corp senior vice president of human resources Paula Green reported an open-market sale of common stock. On February 17, 2026, she sold 39,404 shares at a weighted average price of $52.40 per share, and held 126,041 shares afterward.
Twist Bioscience Corp President and COO Patrick John Finn reported multiple transactions in the company’s stock. On February 17, 2026, he exercised two stock options covering 32,300 and 18,205 shares of common stock.
On the same date, he sold a total of 68,967 shares of common stock in open-market transactions at weighted average prices of $50.321, $51.423, $52.686 and $53.110 per share under a pre-established Rule 10b5-1 trading plan adopted on May 13, 2025. After these transactions, he directly owned 287,788 shares of Twist Bioscience common stock.
Twist Bioscience director Robert Chess reported a small tax-related share sale. On February 13, 2026, 2,184 shares of Twist Bioscience common stock were sold at $48.261 per share to cover tax liabilities arising from the vesting of restricted stock units, pursuant to a prior election rather than a discretionary trade. Following this transaction, Chess directly held 21,084 common shares. He also indirectly held 42,528 common shares through the Chess 1997 Trust, where he and his spouse serve as the sole trustees and beneficiaries.
Twist Bioscience insider Paula Green filed a Form 144 to sell up to 16,739 shares of common stock through Fidelity Brokerage Services LLC on or around 02/17/2026 on NASDAQ, with an aggregate market value of 877,123.60.
The notice shows these shares against a baseline of 61,311,704 common shares outstanding. The securities to be sold were mainly acquired through restricted stock vesting and one employee stock purchase plan transaction between 09/19/2024 and 02/20/2025, generally as compensation.
The filing also lists prior sales by Paula Green over the past three months, totaling 2,942 common shares on several dates, for combined gross proceeds of 109,727.69. By signing, the seller represents having no undisclosed material adverse information about Twist Bioscience’s operations.
A person associated with symbol TWST has filed a Form 144 notice to sell 22,665 shares of common stock. The planned sale, through Fidelity Brokerage Services LLC on NASDAQ, has an aggregate market value of $1,187,646.00 and an approximate sale date of 02/17/2026.
The filing lists 61,311,704 shares outstanding for this class of common stock; this is a baseline figure, not the amount being sold. The notice also discloses prior sales over the past three months by the same person, consistent with Rule 144 reporting requirements.
Twist Bioscience insider Patrick Finn filed a notice of proposed sale of 68,967 shares of the company’s common stock under Rule 144. The shares have an aggregate market value of $3,562,414.66 and are to be sold through Fidelity Brokerage Services LLC on NASDAQ.
The filing notes that 61,311,704 shares of common stock were outstanding, providing context for the planned sale. It also lists how Finn acquired these securities over time, including option grants and exercises, restricted stock vesting, and employee stock purchase plan participation, as well as his common stock sales in the prior three months.